> top > docs > PubMed:15008605 > annotations

PubMed:15008605 JSONTXT

Annnotations TAB JSON ListView MergeView

DisGeNET

Id Subject Object Predicate Lexical cue
T0 38-43 gene:7852 denotes CXCR4
T1 80-143 disease:C0023434 denotes B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
T2 48-52 gene:1236 denotes CCR7
T3 80-143 disease:C0023434 denotes B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
R1 T0 T1 associated_with CXCR4,B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
R2 T2 T3 associated_with CCR7,B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma

DisGeNET5_gene_disease

Id Subject Object Predicate Lexical cue
15008605-0#38#43#gene7852 38-43 gene7852 denotes CXCR4
15008605-0#48#52#gene1236 48-52 gene1236 denotes CCR7
15008605-0#80#143#diseaseC0023434 80-143 diseaseC0023434 denotes B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
15008605-7#211#216#gene2833 1360-1365 gene2833 denotes CXCR3
15008605-7#251#256#diseaseC0023434 1400-1405 diseaseC0023434 denotes B-CLL
38#43#gene785280#143#diseaseC0023434 15008605-0#38#43#gene7852 15008605-0#80#143#diseaseC0023434 associated_with CXCR4,B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
48#52#gene123680#143#diseaseC0023434 15008605-0#48#52#gene1236 15008605-0#80#143#diseaseC0023434 associated_with CCR7,B-cell chronic lymphocytic leukemia/ small lymphocytic lymphoma
211#216#gene2833251#256#diseaseC0023434 15008605-7#211#216#gene2833 15008605-7#251#256#diseaseC0023434 associated_with CXCR3,B-CLL

PubMed_Structured_Abstracts

Id Subject Object Predicate Lexical cue
T1 156-288 OBJECTIVE denotes To assess the clinical relevance of chemokine receptor expression on the progression of B-cell chronic lymphocytic leukemia (B-CLL).
T2 311-976 METHODS denotes Peripheral blood mononuclear cells from 45 patients with B-CLL were purified and compared with lymph node samples collected from 17 of these patients. Also compared were B cells obtained from peripheral blood samples from 5 healthy controls and B cells from reactive lymph nodes from 3 otherwise healthy persons. The patients were treated at the Mayo Clinic in Rochester, Minn, between January 15,1991, and February 7, 2003. Mononuclear cells were stained by a 2-color (fluorescein isothiocyanate/phycoerythrin) flow cytometric assay using antibodies to the chemokine receptors (CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CCR2, CCR4, CCR5, CCR6, and CCR7) and also to CD19.
T3 986-1777 RESULTS denotes Of the 45 patients in this study, 20 had Rai stage 0 disease, 12 had stage I disease, 3 had stage II disease, 2 had stage III disease, and 8 had stage IV disease. The mean fluorescent intensity (MFI) of the chemokine receptor expression on B-CLL cells was compared with normal controls and was not significantly different, except for an increase in the median expression of CXCR3 (P = .003) and CCR7 (P = .001) on B-CLL cells. We also found a significant increase in the expression of CXCR4 and CCR7 in B-CLL cells from patients with stage IV compared with stage 0 disease (P = .001 and P = .02, respectively). Furthermore, circulating B-CLL cells showed significantly higher expression of CXCR4 and CCR7 when compared with B lymphocytes in lymph nodes (P = .003 and P < .001, respectively).
T4 1790-2118 CONCLUSIONS denotes The expression of CXCR4 and CCR7 on B-CLL cells correlates with Rai stage. Also, these chemokine receptors may be down-regulated once malignant B cells enter the lymph nodes. To our knowledge, this is the first published report that shows the strong association of Rai stage with CXCR4 and CCR7 expression levels in B-CLL cells.